,0,1
0,french enterprise,9.0
1,hereditary angioedema,8.866666666666667
2,combination attribution,8.636363636363637
3,single digit,8.592592592592592
4,owned subsidiary,8.545454545454545
5,tax authority,8.416666666666666
6,retinoschisis xlrs,8.4
7,additional funding,8.25561497326203
8,deemed definite lived,8.225
9,deprecation charge,8.222222222222221
10,irrevocable license,8.158371040723981
11,debt financing,8.153333333333334
12,combination service,8.149606299212598
13,vegf program,8.148148148148149
14,accounting pronouncement,8.13888888888889
15,consolidated statements,8.13797372584084
16,sustained expression,8.11111111111111
17,fa cns,8.095238095238095
18,average period,8.086206896551724
19,traded security,8.077777777777778
20,lived assets,8.053571428571429
21,utility parking maintenance,8.035714285714285
22,cash flows,8.032758620689656
23,incremental expense,8.011027359017309
24,webster professor,8.0
25,visual outcome,8.0
26,patient enrollment,8.0
27,upfront payment,7.998427672955975
28,annapurna therapeutics,7.986301369863014
29,line basis,7.974025974025974
30,continuing pre clinical,7.972527472527473
31,ticker symbol,7.972222222222222
32,efficacy,7.972222222222222
33,research,7.967625899280575
34,research committee,7.967625899280575
35,professional fee,7.961598224195338
36,balance sheet arrangements,7.948275862068965
37,business combinations,7.925
38,unrealized loss,7.909090909090909
39,durable efficacy,7.904761904761905
40,proceeding reorganization,7.888888888888889
41,technical corrections,7.883720930232558
42,additional billing,7.876383951244286
43,accounting policy,7.861111111111112
44,month,7.856682769726248
45,substantial expenditure,7.855555555555555
46,average assumption,7.842105263157895
47,service fee,7.828851582231466
48,additional funding,7.811170528817587
49,weill cornell,7.785714285714286
50,clinical material,7.78021978021978
51,financial instrument,7.775028121484814
52,preferred stock,7.7659176029962556
53,stock warrant,7.7659176029962556
54,approval promotion,7.762422360248447
55,additional personnel,7.757575757575758
56,term investments,7.75531914893617
57,administrative expense,7.748401096391046
58,month,7.729275362318841
59,rise,7.729166666666667
60,month,7.7098814229249015
61,development expenses,7.698412698412698
62,adequate funding,7.6900790166813
63,regulatory authority,7.686231884057971
64,insurance policy,7.67912565398599
65,filing prosecuting defending,7.678571428571429
66,projection,7.677777777777778
67,drug application ind,7.677777777777778
68,drug ind application,7.677777777777777
69,stock par,7.672968885047537
70,common stock,7.672968885047537
71,review committee,7.666666666666667
72,dilutive security,7.663636363636363
73,single digit,7.651416122004357
74,maintenance fee,7.637578616352202
75,administrative expense,7.630754037567517
76,dr crystal,7.629787234042553
77,basis,7.6103896103896105
78,park california,7.6
79,cash flow,7.596394984326019
80,month pursuant,7.590301003344481
81,forma result,7.585714285714285
82,money,7.580952380952381
83,ind meeting,7.5777777777777775
84,financial officer,7.577225923682616
85,public offering,7.575882352941177
86,court approval,7.574675324675324
87,discount commission,7.571428571428571
88,consolidated statement,7.556341072779617
89,preclinical study,7.547348484848484
90,operating officer,7.526223776223776
91,initial payment,7.5071996027805366
92,investor relation cost,7.504761904761905
93,development timeline,7.504273504273504
94,volatility,7.5
95,plaintiff,7.499145299145299
96,financial interest,7.4979718444285375
97,product quantity,7.496309963099631
98,net cash,7.493723532970357
99,fraction amount,7.488636363636363
100,program,7.481481481481482
101,licensed product,7.4717197991652045
102,retinal disease,7.469924812030075
103,wa publicly announced,7.467792680907435
104,lived asset,7.465490797546012
105,initial indication,7.461111111111111
106,equipment net,7.459135643988018
107,teen percentage,7.458823529411765
108,legal proceedings,7.446666666666667
109,licensed patent,7.4361941497910635
110,commercial supply,7.435028248587571
111,legal proceedings,7.427272727272728
112,employee,7.425
113,license fee,7.420949657076183
114,weighted average fair,7.396153846153846
115,annapurna therapeutics,7.386301369863014
116,money market fund,7.386225266362253
117,security bid,7.383333333333333
118,fa systemic expired,7.38095238095238
119,accounting policies,7.3788888888888895
120,substantial expense,7.372138470128419
121,tax service rent,7.3718285214348205
122,average number,7.37037037037037
123,equipment,7.369467028003614
124,equipment,7.369467028003614
125,toxicology study,7.365530303030303
126,exchange ratio holders,7.359090909090909
127,exchange commission sec,7.359090909090909
128,clinical study,7.338057775557775
129,worldwide license,7.32760180995475
130,additional infrastructure,7.324242424242423
131,anti vegf,7.319148936170213
132,facility allocation,7.302836052836053
133,net loss,7.295055821371611
134,net loss,7.295055821371611
135,annual period,7.294540229885058
136,transfert inserm,7.276190476190476
137,drug development,7.271746031746032
138,cash flows cash,7.26551724137931
139,regulatory approval,7.262422360248447
140,stock offering,7.2584666226040975
141,intellectual property,7.245270605926343
142,comprehensive loss,7.242424242424242
143,preclinical study,7.241792929292929
144,net sale,7.234704408079022
145,remaining advance,7.233686917389907
146,development expense,7.230681887495367
147,early application,7.227519379844962
148,financial statement,7.225378410854294
149,market development,7.22352685366384
150,product candidate,7.202192316040808
151,price allocation,7.18848347419776
152,interest expense,7.186906259756545
153,development service,7.18135233095863
154,development service budget,7.18135233095863
155,gene therapy trial,7.1719280560271645
156,lawsuit assert claim,7.166666666666667
157,termination fee,7.164093767867352
158,written notice,7.160233918128656
159,intellectual property,7.155335630195966
160,financial information,7.152725349629804
161,cash charge,7.146011258802629
162,revenue recognition,7.143262411347518
163,result overview,7.141269841269841
164,research fee,7.137780273208534
165,officer insurance premium,7.135531135531137
166,subtopic disclosure,7.11888111888112
167,accounting policy,7.101111111111112
168,future payment,7.100843131893173
169,capital stock,7.099250936329588
170,management,7.097288676236046
171,capital stock,7.092448215241152
172,material production,7.085470085470085
173,drug administration,7.081871345029239
174,original award,7.0649350649350655
175,contingent payment,7.051457975986278
176,acquisition cash equivalents,7.035575522098106
177,asu defines,7.033327229445157
178,purchase price,7.033083318797604
179,retrospective approach,7.033026755852843
180,period,7.032873563218391
181,leasing activity,7.029347826086957
182,year license,7.026984179410112
183,additional fund,7.018686868686869
184,overview summary,7.013123359580052
185,common stock,7.0063022183808705
186,interest income,6.997668997668997
187,acquisition,6.984635083226633
188,current liability,6.961038961038961
189,sale import export,6.959850606909431
190,preclinical proof,6.956277056277056
191,written claim,6.941666666666666
192,consulting audit,6.923076923076923
193,stock refer,6.922968885047537
194,commercialization,6.921683097427989
195,milestone payment,6.92105112766868
196,market demand,6.919053549190536
197,term nature,6.9132138857782754
198,master service agreement,6.909382835525447
199,fasb issued asu,6.907530454042082
200,clinical trial,6.905915630422209
201,undivided interest,6.903453136011276
202,manufacturing activity,6.90187529861443
203,conditional advance,6.900353584056574
204,impairment charge,6.895708778463851
205,considered indefinite lived,6.889285714285714
206,income expense net,6.882035006340745
207,preclinical study,6.880681818181818
208,securities act,6.868070953436806
209,manufacturing facility,6.862179487179487
210,global market,6.858447488584475
211,nervous system,6.857142857142857
212,retrospective approach,6.850961538461538
213,common share,6.850010283833813
214,price consideration,6.845049130763416
215,early adoption,6.843912822467912
216,early adoption,6.843912822467912
217,preferred share,6.841768525592055
218,exchange act,6.840798226164079
219,gene therapy product,6.840113019126796
220,therapeutic material,6.822843822843823
221,liability,6.817927170868347
222,tax authority,6.816666666666666
223,november regeneron,6.807560137457045
224,company,6.804834300409522
225,research period,6.8038327958322995
226,administrative expenses,6.798484848484848
227,inserm transfert,6.797871774408087
228,allergy program,6.794346978557504
229,identifiable asset,6.792871749926965
230,clinical trial,6.79195682035356
231,financial information,6.791931553248581
232,cornell,6.791403286978508
233,written notice,6.79078947368421
234,agreement,6.787554314090627
235,trial annapurna,6.786953842390487
236,amortization expense,6.785391108241393
237,license agreement,6.784814243703497
238,stock plans,6.765917602996255
239,securities exchange act,6.757649667405765
240,regenxbio,6.755689001264223
241,preclinical trial,6.751569976076555
242,marketable security,6.747742733457019
243,research period,6.746140488139992
244,accounting pronouncements,6.738888888888889
245,cornell university,6.736263736263736
246,development expense,6.733803806654091
247,expense impairment,6.730857236741922
248,research agreement,6.727402435593424
249,price,6.716931216931217
250,annapurna option,6.71689497716895
251,balance sheet date,6.698275862068965
252,substantive option,6.6948793215916504
253,sell product,6.691962137012674
254,net cash,6.691894264677673
255,lease agreement,6.688347964884278
256,aav vector,6.687500000000001
257,rare disease,6.677631578947368
258,early adoption,6.677246155801245
259,product candidate,6.6747197885682805
260,related expense,6.66284208863355
261,party service provider,6.649606299212598
262,biopharmaceutical company,6.648546144121365
263,price,6.643518518518518
264,million partially offset,6.638190595387091
265,based approach,6.637676344305868
266,milestone payment,6.637271182587723
267,equity interest,6.636363636363637
268,comprehensive loss,6.627899102759438
269,milestone fee,6.627313417626263
270,retrospective approach,6.625
271,gene therapy,6.613033825257935
272,milestone regeneron,6.5947087318345545
273,contract manufacturing organization,6.592171717171717
274,gene vector development,6.591557859703021
275,related expense,6.590946663796949
276,cash cash,6.5905172413793105
277,goodwill impairment,6.588358918128654
278,net property,6.580347765200139
279,fa program,6.576719576719578
280,milestone payment,6.568909600666817
281,development milestone payment,6.567322299079516
282,quarterly amount,6.564547294810453
283,material breach,6.547692307692308
284,year,6.545861815934808
285,intangible assets,6.5357142857142865
286,significant agreements,6.526833855799373
287,indemnification obligation,6.51865749426725
288,gene therapy expertise,6.5104697226938315
289,internal research,6.489603921258597
290,agreement,6.487485452746276
291,continued research,6.482777414432091
292,million wa received,6.480089218511924
293,reporting period,6.47635841170324
294,annapurna option,6.46689497716895
295,commercialization milestone payment,6.460949401661843
296,administrative expense,6.448401096391046
297,product basis,6.445745773191178
298,stockholder defendant,6.444444444444445
299,genetic disease,6.442543859649122
300,aggregate amount,6.438636363636363
301,lease obligation,6.433797909407666
302,early adoption,6.427246155801245
303,additional share,6.427065371603186
304,invoice regeneron quarterly,6.42294475284166
305,estimated liability,6.422360248447204
306,goodwill,6.418180128391121
307,recognize million ratably,6.415501519756839
308,research term,6.415252740524438
309,cornell university,6.414872798434443
310,december,6.413057583130575
311,year,6.413057583130575
312,product revenue,6.410160609741267
313,administration treatment,6.407797270955165
314,generate revenue,6.405154994467723
315,stock option,6.403562492353473
316,government agency security,6.3999999999999995
317,reporting company,6.393389536023581
318,sale price,6.385776532835356
319,remaining million allocated,6.379787234042553
320,market data,6.379280821917808
321,disease indication,6.370731473492474
322,milestone payment,6.3631624742300374
323,sufficient fund,6.343589743589744
324,recurring adjustment,6.340067340067341
325,year beginning,6.334192848831059
326,indication indications,6.330158730158731
327,impairment wa recorded,6.322511268741999
328,licensed product,6.320459294963524
329,development expense research,6.315954845599471
330,operating expense,6.31203746002741
331,based compensation,6.309035347606536
332,federal action,6.305092186128182
333,product candidate,6.303887231295045
334,clinical trial,6.300652472527473
335,alpha antitrypsin deficiency,6.295238095238095
336,increased cost,6.29187675070028
337,asset goodwill,6.27575865468887
338,development ipr amp,6.270634920634921
339,purchase price,6.2696523053665905
340,annapurna options,6.2613013698630136
341,obligation table,6.255226480836237
342,quarter,6.254358974358974
343,based award,6.253479792050981
344,million post,6.2524522402692035
345,deferred revenue,6.231141199226305
346,security liquidity,6.221212121212121
347,standard update,6.208037825059101
348,employee,6.206747445949157
349,stock option,6.206656137838422
350,license agreement,6.203861862751117
351,allergy license agreement,6.195925354814609
352,advm study,6.192693236714976
353,banque publique,6.1875
354,million wa excluded,6.181462216223594
355,reporting period,6.179789784252259
356,net asset,6.178836662207667
357,common stock,6.178657886311759
358,interim period,6.171884645912338
359,effective date,6.169117647058823
360,license agreement regenxbio,6.168147577036831
361,management,6.165907557354926
362,stock option award,6.163177876968858
363,stock option,6.163177876968858
364,development activity,6.15752242926156
365,future payment,6.156398687448728
366,period,6.152873563218391
367,development stage milestone,6.152227959456875
368,goodwill,6.151539112615823
369,intangible asset,6.1500146070698225
370,stock option,6.149479246831871
371,company,6.146939563567416
372,net proceeds,6.140752146323255
373,separation agreement,6.138347964884277
374,development program,6.132275132275133
375,ava,6.116666666666667
376,stock option,6.102571816362797
377,asu revenue,6.099710614307349
378,director,6.097727272727273
379,term investment,6.097424412094065
380,business entity,6.095168067226891
381,purchase approximately million,6.094248880770209
382,biotechnologies,6.08994708994709
383,credit loss,6.075757575757575
384,february regeneron,6.074226804123711
385,ava,6.061227024341779
386,clinical trial,6.058716988656505
387,service,6.0510486069049065
388,company,6.045524166099387
389,advance payment,6.035321377806335
390,warrant,6.033333333333333
391,regulatory goal,6.031103678929766
392,exclusivity obligation editas,6.025482344375683
393,treatment option,6.019482496194825
394,revenue recognition process,6.018262411347518
395,acquisition valuation,6.0113404934936865
396,product candidate,6.002192316040808
397,patent term,5.988830735388933
398,sale security,5.969635018186379
399,agreement annapurna,5.965590101297814
400,product basis,5.956637306988618
401,effective maturity,5.955882352941177
402,litigation,5.9523809523809526
403,revenue recognition requirement,5.950954719039825
404,effective date,5.93048128342246
405,party cornell university,5.928571428571429
406,ataxia license agreement,5.91814757703683
407,wa,5.913904910161835
408,license agreement annapurna,5.904448946899844
409,development expense,5.903884501874451
410,cornell university,5.8901098901098905
411,development service unit,5.885056034662334
412,development milestone,5.879500686729603
413,option exercise price,5.878741755454084
414,operating result,5.872473178994918
415,product,5.8540727403416755
416,product sale,5.84504945889795
417,analysis,5.841463414634147
418,preclinical study,5.840031411677753
419,wa,5.824863387978142
420,commercialization effort,5.82193984445439
421,business model research,5.821197327852004
422,event,5.81904761904762
423,adoption acquisition,5.810514691857489
424,million wa attributed,5.804650622020696
425,source,5.794047619047619
426,april annapurna,5.769189070397773
427,deferred revenue,5.754626047711154
428,annapurna hold,5.746077906175863
429,financing arrangement,5.732121212121212
430,ipr amp,5.705555555555556
431,licensing revenue,5.704361777098047
432,research cost,5.700457979481077
433,expiration lapse abandonment,5.696581196581196
434,research term research,5.690570947497321
435,management,5.688924093958418
436,acquisition closing date,5.682446531038081
437,deficiency license agreement,5.680052338941593
438,financial asset,5.615518919030826
439,company patent university,5.6093304578468555
440,financial liability,5.595980502437195
441,asset liability revenue,5.593277018417339
442,license agreement,5.584814243703498
443,option exercise period,5.557541244598401
444,development effort advance,5.552108022696258
445,period,5.549027409372236
446,december annapurna,5.548927632489276
447,million wa included,5.5478200209278
448,nature amount timing,5.530677441941883
449,development cost,5.479466938290467
450,annapurna acquisition,5.418905505314017
451,goodwill,5.415672408343869
452,goodwill impairment analysis,5.402044554985023
453,million share,5.377343936974509
454,company,5.376262871838093
455,royalty payment,5.365004894184358
456,asset approximates,5.364300321355536
457,share,5.347457526856277
458,company stock issuance,5.34252859007608
459,company,5.340548586123807
460,company,5.335476235306777
461,acquisition method,5.290379090463177
462,significant estimate,5.282682926829269
463,consecutive month,5.282608695652174
464,year performance period,5.267320035237855
465,july annapurna,5.23305461661626
466,definite lived,5.225
467,termination cost,5.221494447581404
468,initial application,5.15
469,company,5.1354762353067755
470,regulatory authority,5.119565217391305
471,applicable country,5.118654311039484
472,amended provided,5.094512195121951
473,financial statements,5.0607424071991005
474,incur substantial,5.055555555555555
475,minimum threshold,5.0476190476190474
476,inserm transfert,5.038095238095238
477,cash flows,5.0327586206896555
478,accrued liability,5.02263856362217
479,partially offset,5.008403361344538
480,share,5.004203558602309
481,audit,5.0
482,banque publique,5.0
483,upfront payment,4.998427672955975
484,payment,4.970649895178196
485,company,4.967334642386422
486,publicly announced,4.959595959595959
487,balance sheet,4.948275862068965
488,indefinite lived,4.925
489,quoted price,4.907407407407407
490,approval,4.892857142857142
491,preclinical proof,4.8896103896103895
492,consolidated statement,4.878921717940908
493,consolidated complaint,4.871268656716418
494,accounting policy,4.861111111111111
495,administration procedure,4.859649122807017
496,wa received,4.85030198446937
497,gene therapy,4.8438030560271645
498,administration expense,4.842898704046549
499,stock price,4.839991677070328
500,license fee,4.83761632374285
501,public offering,4.825882352941177
502,income approach,4.804487179487179
503,interest expense,4.801431399421349
504,clinical trial,4.800652472527473
505,company,4.80039357205575
506,increasing expenditure,4.8
507,fasb voted,4.791666666666666
508,clinical expense,4.789110387100337
509,weill cornell,4.785714285714286
510,twelve month,4.782608695652174
511,financial assets,4.775028121484814
512,financial instrument,4.775028121484814
513,intellectual property,4.76986076986077
514,regulatory approval,4.762422360248447
515,early adoption,4.760579489134578
516,material production,4.752136752136752
517,administrative expense,4.748401096391046
518,early stage,4.7441860465116275
519,charge equal,4.738304093567251
520,purchase price,4.733938019652305
521,month revenue,4.7258711069996915
522,obligation,4.719512195121951
523,written notice,4.715789473684211
524,fa systemic,4.7142857142857135
525,license agreements,4.703825586178527
526,interest,4.695374800637959
527,sublicense fee,4.679245283018868
528,common stock,4.672968885047537
529,capital,4.666666666666667
530,human primate,4.666666666666667
531,accrued expenses,4.666666666666666
532,tax position,4.666666666666666
533,tax purpose,4.666666666666666
534,specific personnel,4.666666666666666
535,credit losses,4.666666666666666
536,interest income,4.664335664335664
537,patent,4.655228758169935
538,activity,4.654347826086957
539,securities,4.648558758314856
540,cash payment,4.647852960312297
541,research fee,4.646871182299443
542,severe allergy,4.646198830409356
543,basis,4.640692640692641
544,original award,4.636363636363637
545,payment obligation,4.634606534744593
546,lawsuit,4.625
547,generally occurs,4.625
548,post annapurna,4.62266500622665
549,exchange act,4.621286031042128
550,basis,4.6103896103896105
551,payment,4.602594339622641
552,remains uncured,4.6
553,market price,4.5991882293252155
554,cash flow,4.596394984326019
555,internal system,4.593406593406593
556,cornell pursuant,4.593406593406593
557,single injection,4.592592592592593
558,wa comparable,4.591530054644808
559,goodwill,4.586321721311475
560,rs gene,4.580645161290322
561,fa program,4.576719576719577
562,cash,4.57486388384755
563,court approval,4.574675324675324
564,single vector,4.5717592592592595
565,insurance coverage,4.571428571428571
566,insurance carrier,4.571428571428571
567,factor,4.566666666666666
568,cash,4.566091954022989
569,net income,4.565452091767881
570,income net,4.565452091767881
571,therapy,4.562303193882141
572,substantial doubt,4.555555555555555
573,anticipated synergy,4.555555555555555
574,substantial damage,4.555555555555555
575,stock offering,4.552584269662921
576,scientific meeting,4.55
577,preclinical study,4.547348484848484
578,jointly owned,4.545454545454545
579,company,4.545312300880546
580,ii retrospective,4.538461538461538
581,closing price,4.537037037037037
582,fund,4.536549707602339
583,milestone payment,4.535576267333485
584,related service,4.535081159547794
585,alpha antitrypsin,4.533333333333333
586,manufacturing facility,4.528846153846153
587,restructuring charge,4.527777777777778
588,accounting related,4.524363749224085
589,valuation security,4.522222222222222
590,wa incorporated,4.508196721311475
591,wa le,4.508196721311475
592,patent,4.506238859180035
593,contractual obligation,4.505226480836237
594,clinical development,4.504273504273504
595,united states,4.5
596,regulatory milestone,4.490047145102148
597,aggregate balance,4.4816091954022985
598,financial statement,4.479109754137875
599,licensed product,4.4717197991652045
600,record charge,4.468954248366013
601,amortization,4.468808193668529
602,initial indication,4.461111111111111
603,september,4.45954893440927
604,limited activity,4.4543478260869565
605,operating facility,4.449300699300699
606,development payment,4.446840371368673
607,related information,4.445474860335196
608,institutional stockholder,4.444444444444445
609,scale production,4.444444444444445
610,company,4.440560981069488
611,post acquisition,4.439180537772087
612,expense,4.436582914572865
613,licensed patent,4.4361941497910635
614,stock modification,4.432584269662922
615,stock award,4.432584269662922
616,manufacturing activity,4.429347826086957
617,ataxia,4.428571428571429
618,cornell university,4.428571428571429
619,option,4.425038051750381
620,primarily relates,4.421296296296296
621,marketable security,4.421212121212121
622,payment schedule,4.415094339622641
623,revenue,4.413850646641635
624,quarterly report,4.410256410256411
625,incur loss,4.409090909090909
626,financial information,4.406456692913386
627,amortization expense,4.399916247906198
628,option,4.397260273972602
629,conditional advance,4.392156862745098
630,product approval,4.389167105956774
631,related project,4.385474860335195
632,award,4.385474860335195
633,goodwill,4.377270299145299
634,excluded warrant,4.3768115942028984
635,security,4.375
636,financing activity,4.374347826086956
637,compensation expense,4.372138470128419
638,regulatory function,4.369565217391305
639,continuing decrease,4.369565217391305
640,regulatory affair,4.369565217391305
641,impairment related,4.367931000686072
642,hae,4.366666666666667
643,exchange ratio,4.359090909090909
644,cash,4.357758620689655
645,viral vector,4.354166666666667
646,cash milestone,4.353240548400499
647,related research,4.353100759615771
648,sufficient quantity,4.35
649,preclinical development,4.34992784992785
650,operating activity,4.349802371541502
651,development expense,4.348328946318896
652,financial position,4.346456692913385
653,financial liabilities,4.346456692913385
654,financial instruments,4.346456692913385
655,patent,4.346259174060686
656,wa recorded,4.340055128391121
657,accounting options,4.338888888888889
658,incur cost,4.338095238095238
659,additional disclosure,4.337062937062937
660,capital,4.333333333333334
661,remains outstanding,4.333333333333334
662,capital resources,4.333333333333334
663,control premium,4.333333333333334
664,human patient,4.333333333333334
665,june,4.332141527001863
666,wa based,4.3290922436995345
667,revenue,4.328737271682713
668,exclusive license,4.327601809954751
669,agreement,4.326443202979516
670,ongoing consideration,4.325396825396826
671,licensed technology,4.323894684550422
672,financing activities,4.32
673,accrued expense,4.316582914572864
674,qualified expense,4.316582914572864
675,aav vector,4.3125
676,rare disease,4.309210526315789
677,million fee,4.309032517061421
678,wet amd,4.3076923076923075
679,transaction price,4.307407407407407
680,potentially revenue,4.306898774983882
681,benchmark security,4.3
682,treasury security,4.3
683,ha devoted,4.299145299145299
684,institution,4.299145299145299
685,single unit,4.296296296296296
686,operating activities,4.295454545454545
687,net loss,4.29505582137161
688,annual period,4.294540229885058
689,sale organization,4.2931839402427645
690,research expense,4.28420881385344
691,annapurna offset,4.280419016921837
692,open ind,4.277777777777778
693,accounting identified,4.272222222222222
694,advm,4.271367521367521
695,annual compensation,4.263888888888889
696,therapy,4.2631578947368425
697,avalanche biotechnologies,4.262108262108262
698,potential license,4.260065955978219
699,marketable securities,4.257575757575758
700,biotechnologies,4.256613756613756
701,company,4.255689001264223
702,net decrease,4.255530129672006
703,utility research,4.253340184994861
704,manufacturing process,4.25
705,year,4.249565519638512
706,product,4.246309963099631
707,market activity,4.246128648004765
708,comprehensive loss,4.242424242424242
709,common stockholder,4.240384615384615
710,significant judgments,4.24
711,significant influence,4.24
712,ipr amp,4.238888888888889
713,liability assets,4.238095238095238
714,net sale,4.234704408079021
715,technology,4.233959708820044
716,existing cash,4.232758620689655
717,cash receipts,4.232758620689655
718,cash receipt,4.232758620689655
719,disclosures,4.232142857142858
720,related disclosure,4.231628706489042
721,net asset,4.226455709826714
722,asset,4.225965657881208
723,operating lease,4.224025974025974
724,wa applied,4.22248243559719
725,indemnification obligation,4.219512195121951
726,public company,4.211571354205399
727,related management,4.210036263843968
728,annual test,4.208333333333334
729,adverum,4.204761904761905
730,operating loss,4.204545454545455
731,product candidate,4.202192316040808
732,additional indication,4.2020202020202015
733,patient suffering,4.2
734,separate recognition,4.2
735,alpha project,4.2
736,safety issue,4.2
737,transaction,4.199145299145298
738,intangible asset,4.19763365468887
739,liability,4.194998669859005
740,market acceptance,4.191780821917808
741,market capitalization,4.191780821917808
742,separation agreement,4.188347964884278
743,requires substantially,4.1875
744,concept data,4.1875
745,data package,4.1875
746,financial asset,4.1869474904593975
747,annapurna options,4.186301369863013
748,cash,4.185139573070607
749,information item,4.1850000000000005
750,ophthalmologic disease,4.184210526315789
751,ocular disease,4.184210526315789
752,disease,4.184210526315789
753,annual basis,4.182359307359308
754,commercial sale,4.182072829131653
755,superior court,4.181818181818182
756,therapeutic protein,4.181818181818182
757,executive officer,4.180769230769231
758,development program,4.17989417989418
759,taxable income,4.179487179487179
760,stock option,4.163177876968858
761,fund research,4.16207034372502
762,fiscal year,4.160279805352798
763,license extends,4.158371040723981
764,innovative nature,4.157894736842105
765,period,4.152873563218391
766,development milestone,4.152227959456875
767,service,4.149606299212598
768,sale security,4.148739495798319
769,recorded expense,4.148441321652511
770,exercise price,4.148148148148148
771,level price,4.143518518518519
772,achievable subsequent,4.142857142857142
773,indications,4.139303482587065
774,modification accounting,4.138888888888889
775,wa million,4.137983955354029
776,million wa,4.137983955354029
777,operating asset,4.135945343000557
778,misleading statement,4.13265306122449
779,effort,4.128205128205129
780,research license,4.1259969400045575
781,complaint,4.125
782,business strategy,4.125
783,event,4.119047619047619
784,equity security,4.118181818181818
785,research service,4.117232198493174
786,editas,4.113662456946039
787,consideration,4.111111111111111
788,variable consideration,4.111111111111111
789,planned upgrade,4.105263157894736
790,editas,4.10511544839903
791,acquisition,4.10196220055375
792,license,4.097764980117921
793,interim reporting,4.093582887700535
794,development activity,4.086093857832989
795,amount,4.080741626794258
796,deferred revenue,4.0796260477111534
797,test goodwill,4.078125
798,future period,4.077511244377812
799,financial condition,4.075623359580052
800,canceled prior,4.075
801,settled prior,4.075
802,corporate source,4.075
803,current guidance,4.074592074592075
804,laboratory equipment,4.073170731707317
805,equipment purchases,4.073170731707317
806,uncertainty,4.066666666666666
807,outstanding option,4.06392694063927
808,goodwill impairment,4.060581140350877
809,historical information,4.0600000000000005
810,legal action,4.0588235294117645
811,common equity,4.058566433566433
812,foreseeable future,4.057971014492754
813,editas,4.0559701492537314
814,service,4.054368203974503
815,activity,4.054347826086957
816,research period,4.0538327958322995
817,commercialization milestone,4.045855062039202
818,cornell agreement,4.045490822027135
819,sufficient fund,4.044444444444444
820,level security,4.036111111111111
821,aggregate intrinsic,4.033333333333333
822,licensing agreement,4.032503809040122
823,development,4.031746031746032
824,discontinue development,4.031746031746032
825,development initiative,4.031746031746032
826,product development,4.028055994845663
827,potential commercialization,4.027068049582596
828,editas obligation,4.025482344375683
829,research activity,4.021973725367532
830,effect,4.019444444444445
831,revenue,4.018262411347518
832,million related,4.015262094377748
833,extension fee,4.012578616352201
834,vector development,4.010912698412699
835,regenxbio agreement,4.009776536312849
836,wa expected,4.008196721311475
837,annual report,4.003205128205129
838,accumulated deficit,4.0
839,unmet medical,4.0
840,vote,4.0
841,stockholder,4.0
842,clause,4.0
843,significantly revise,4.0
844,temporarily impaired,4.0
845,factor,4.0
846,curve,4.0
847,prepayment,4.0
848,northern district,4.0
849,purported class,4.0
850,san mateo,4.0
851,defendant,4.0
852,insured retention,4.0
853,stockholder,4.0
854,readily measurable,4.0
855,strategic partnership,4.0
856,approved proceed,4.0
857,discernible pattern,4.0
858,profitable depends,4.0
859,highly uncertain,4.0
860,historical experience,4.0
861,readily apparent,4.0
862,larger scale,4.0
863,people,4.0
864,informational purpose,4.0
865,office space,4.0
866,practical expedients,4.0
867,patient living,4.0
868,frequent injection,4.0
869,practical expedient,4.0
870,chiron corporation,4.0
871,diligently proceed,4.0
872,involuntary petition,4.0
873,office building,4.0
874,fault wrongdoing,4.0
875,positive control,4.0
876,agree annually,4.0
877,interim period,3.9979716024340775
878,agreement inserm,3.9978717744080874
879,ophthalmic indication,3.996825396825397
880,product,3.9963099630996313
881,product,3.9963099630996313
882,current asset,3.9920059490611637
883,future partner,3.991304347826087
884,adjustment,3.9894179894179893
885,ireland,3.9863013698630136
886,annapurna hold,3.9863013698630136
887,proprietary vector,3.979166666666667
888,significant amount,3.9786363636363635
889,entirety,3.9747416762342134
890,pretax basis,3.974025974025974
891,collaboration partner,3.972972972972973
892,effective immediately,3.972689075630252
893,annapurna annapurna,3.9726027397260273
894,advm,3.9722222222222223
895,advm,3.9722222222222223
896,advm,3.9722222222222223
897,million received,3.971892497200448
898,accounting recorded,3.970747295968535
899,incurred prior,3.969736842105263
900,collaboration product,3.969282936072604
901,sale milestone,3.969221423509163
902,updated research,3.9676258992805753
903,research institution,3.9676258992805753
904,research participation,3.9676258992805753
905,actual timing,3.9674796747967482
906,option,3.9627364644487932
907,current liability,3.9610389610389607
908,current requirement,3.959207459207459
909,future research,3.9589302471066627
910,service requirement,3.9572986069049065
911,internal medicine,3.956340956340956
912,million purchase,3.956317846287451
913,year period,3.9548200352378555
914,material breach,3.947692307692307
915,june notes,3.9466666666666668
916,action,3.94429838974696
917,revenue earnings,3.9432624113475176
918,outstanding share,3.9429590017825316
919,customers,3.942857142857143
920,research collaboration,3.9405988722535485
921,product revenue,3.939572374447149
922,purchase share,3.936156280694096
923,acquisition closing,3.9324465310380807
924,million ha,3.928932533187852
925,model,3.928571428571429
926,march notes,3.9272727272727272
927,million primarily,3.9260835303388495
928,month anniversary,3.9254658385093166
929,million offset,3.9239048811013766
930,authoritative guidance,3.9230769230769234
931,actual result,3.9190476190476193
932,license agreement,3.918147577036831
933,therapeutic level,3.917929292929293
934,sec summary,3.916666666666667
935,retinal delivery,3.9107142857142856
936,loss contingency,3.909090909090909
937,increasing loss,3.909090909090909
938,regents interest,3.903453136011276
939,transaction,3.9
940,alternative transaction,3.9
941,exclusive option,3.899824376536705
942,annapurna transaction,3.8863013698630136
943,reporting unit,3.8855218855218854
944,asu retains,3.883720930232558
945,material effect,3.8826923076923077
946,amount,3.8814935064935066
947,closing date,3.8796296296296298
948,judgment,3.875
949,aggregate cost,3.871428571428571
950,development cost,3.8698412698412694
951,year deferral,3.8686131386861313
952,calendar year,3.8686131386861313
953,ten year,3.8686131386861313
954,active market,3.858447488584475
955,stock plan,3.8572418039094964
956,subsequent indication,3.8539682539682536
957,common share,3.8500102838338135
958,day notice,3.849122807017544
959,competing technology,3.8484848484848486
960,technology platform,3.8484848484848486
961,innovative technology,3.8484848484848486
962,company,3.8477942644221175
963,product sale,3.8450494588979502
964,december,3.8435897435897433
965,process research,3.8426258992805753
966,share,3.8417685255920553
967,wa drawn,3.8415300546448083
968,planned level,3.841374269005848
969,identical asset,3.8404907975460123
970,similar asset,3.8404907975460123
971,future sale,3.8400438436244064
972,applicable period,3.836206896551724
973,derived principally,3.8333333333333335
974,administered intravitreally,3.8333333333333335
975,lapse,3.833333333333333
976,paying million,3.8297872340425534
977,low teen,3.8285714285714283
978,asu revenue,3.8269833415800756
979,development effort,3.8266178266178263
980,payment,3.8249304051964117
981,project management,3.824561403508772
982,company expense,3.822271915837087
983,acquirer,3.8208955223880596
984,share equal,3.820151984238672
985,day cornell,3.819047619047619
986,equity award,3.8181818181818183
987,time charge,3.8172514619883042
988,option period,3.8168005038576602
989,ann program,3.814814814814815
990,company,3.8133813089565303
991,liability,3.8095238095238093
992,noncurrent liability,3.8095238095238093
993,material default,3.8076923076923075
994,estimated loss,3.8076416337285903
995,regeneron,3.807560137457045
996,import sell,3.8067632850241546
997,company,3.8048343004095218
998,terminate early,3.8021570610043813
999,employee award,3.8
1000,customers,3.8
1001,recorded research,3.7994843063602213
1002,share data,3.7971256684491976
1003,effort,3.7948717948717947
1004,asset,3.792871749926965
1005,nature timing,3.7920410783055196
1006,development agreement,3.791522568058881
1007,annapurna acquisition,3.789118271271464
1008,defined period,3.7862068965517244
1009,genetic medicine,3.781981981981982
1010,additional time,3.780382775119617
1011,editas research,3.7735960485343067
1012,contract companies,3.7727272727272725
1013,aggregate amount,3.7719696969696965
1014,day,3.7714285714285714
1015,approximately million,3.7677182685253117
1016,commercialization cost,3.7634683724235964
1017,indemnification agreement,3.7597765363128492
1018,agreement,3.7597765363128492
1019,target development,3.759018759018759
1020,acceptable term,3.75531914893617
1021,million relates,3.754787234042553
1022,adjusted pursuant,3.752136752136752
1023,april annapurna,3.7510072522159548
1024,disclosure,3.750915750915751
1025,valued primarily,3.750841750841751
1026,table,3.75
1027,table,3.75
1028,net increase,3.7466206499856196
1029,financial assistance,3.7464566929133856
1030,service,3.7433562992125986
1031,advancing advm,3.7414529914529915
1032,accompanying note,3.7413793103448274
1033,thereto,3.7413793103448274
1034,convertible note,3.7413793103448274
1035,full year,3.7381783560774355
1036,lease liability,3.738095238095238
1037,estimated cost,3.7366459627329194
1038,lowest level,3.736111111111111
1039,deficiency,3.734126984126984
1040,cost,3.732832080200501
1041,collaboration agreement,3.7327495092858225
1042,future exercise,3.732045088566828
1043,development,3.731746031746032
1044,recognize revenue,3.7289766970618032
1045,research term,3.7229450482167454
1046,editas,3.7226368159203984
1047,annapurna option,3.7168949771689497
1048,revenue contract,3.71598968407479
1049,evidence,3.7142857142857144
1050,financing arrangement,3.713939393939394
1051,advance annapurna,3.711791565941445
1052,company options,3.705689001264223
1053,time payment,3.7045680238331675
1054,offsetting adjustment,3.7037037037037037
1055,collaboration option,3.703566580278909
1056,revenue agreement,3.703038947660367
1057,target basis,3.7012987012987013
1058,considered level,3.700396825396825
1059,collaboration target,3.7002457002457003
1060,accelerated vesting,3.7
1061,generation,3.7
1062,development portfolio,3.6984126984126986
1063,contractual maturity,3.697478991596639
1064,march april,3.6919786096256684
1065,government grant,3.690909090909091
1066,year,3.689508661074191
1067,time,3.689473684210526
1068,lease agreement,3.6883479648842776
1069,modified award,3.6875
1070,debilitating disease,3.6842105263157894
1071,lease term,3.683890577507599
1072,sale marketing,3.682072829131653
1073,research,3.6819116135662897
1074,director,3.681060606060606
1075,potential effect,3.676694915254237
1076,total intrinsic,3.675
1077,asset,3.6723492046256583
1078,option,3.6699875466998755
1079,respective fair,3.668881118881119
1080,differ materially,3.666666666666667
1081,liability,3.666666666666667
1082,wamd therapy,3.663157894736842
1083,disclosure requirement,3.653846153846154
1084,distribution,3.642857142857143
1085,acquisition cost,3.6409121395036887
1086,outcome timing,3.6341463414634143
1087,amount,3.6333732057416266
1088,entire million,3.629787234042553
1089,delay,3.625
1090,full term,3.624884366327475
1091,event,3.619047619047619
1092,share award,3.6096256684491976
1093,fractional share,3.6096256684491976
1094,full amount,3.608201581027668
1095,contingencies collaborations,3.6
1096,address unmet,3.6
1097,sublicenses,3.590909090909091
1098,primary reason,3.587301587301587
1099,trial,3.586189516129032
1100,historical result,3.5857142857142854
1101,future grant,3.582213438735178
1102,revenue,3.5796260477111543
1103,numerous risk,3.5789473684210527
1104,inherent risk,3.5789473684210527
1105,regents,3.576975691886773
1106,level asset,3.5766019086571235
1107,cumulative effect,3.575
1108,result annapurna,3.5720156555772995
1109,mutually agreed,3.571428571428571
1110,implied fair,3.5628205128205126
1111,acquisition agreement,3.5625934377212998
1112,significant impact,3.5625806451612902
1113,deficiency,3.5619047619047617
1114,underwriter exercise,3.558922558922559
1115,asserted action,3.5588235294117645
1116,necessarily indicative,3.5555555555555554
1117,acquisition date,3.552816901408451
1118,wamd program,3.5481481481481483
1119,fully recoverable,3.5454545454545454
1120,claim,3.541666666666667
1121,automatically terminated,3.541666666666667
1122,claim,3.541666666666667
1123,management,3.538847117794486
1124,option editas,3.5365637565596675
1125,collaboration cover,3.535472972972973
1126,day,3.533333333333333
1127,successful development,3.5317460317460316
1128,fair statement,3.528806907378336
1129,company,3.5238708194460404
1130,successfully develop,3.5172413793103448
1131,discover develop,3.5172413793103448
1132,fixed asset,3.5071574642126793
1133,editas,3.5059701492537316
1134,company,3.505689001264223
1135,company belief,3.505689001264223
1136,company,3.505689001264223
1137,company,3.505689001264223
1138,company,3.505689001264223
1139,entire company,3.505689001264223
1140,company,3.505689001264223
1141,company,3.505689001264223
1142,company,3.505689001264223
1143,company,3.505689001264223
1144,company,3.505689001264223
1145,company,3.505689001264223
1146,combined total,3.502586206896552
1147,patent claim,3.502450980392157
1148,inherent uncertainty,3.5
1149,party,3.5
1150,le transparency,3.5
1151,million decrease,3.4993524514338574
1152,license,3.4917043740573153
1153,occurrence subject,3.488888888888889
1154,tiered royalty,3.488372093023256
1155,product subject,3.48519885198852
1156,adopt asu,3.4837209302325585
1157,leases asu,3.4837209302325585
1158,impairment indicator,3.482456140350877
1159,material respect,3.480106100795756
1160,distribution infrastructure,3.4761904761904763
1161,annapurna subject,3.4751902587519026
1162,situation,3.4742268041237114
1163,activity,3.473702664796634
1164,company patent,3.4664733149897127
1165,entity,3.4642857142857144
1166,recorded million,3.461645641122199
1167,million recorded,3.461645641122199
1168,company,3.458069953645175
1169,development plan,3.456403565992607
1170,editas medicine,3.45461879790238
1171,impairment,3.453044375644995
1172,pending litigation,3.447619047619048
1173,company record,3.446865471852458
1174,company,3.4450829406581622
1175,share,3.4414840755288436
1176,operation regenxbio,3.436274509803922
1177,company lease,3.434260429835651
1178,editas,3.4309701492537314
1179,condition,3.4291666666666667
1180,savings plan,3.4246575342465753
1181,director underwriter,3.424242424242424
1182,unvested rsus,3.4193548387096775
1183,recognize million,3.4155015197568392
1184,employee director,3.4060606060606062
1185,operations,3.4
1186,tier,3.396153846153846
1187,annapurna included,3.396137435436784
1188,research plan,3.392283433527151
1189,determined based,3.3861129136924077
1190,goodwill,3.383209745762712
1191,prior quarter,3.3826923076923077
1192,time period,3.3756805807622507
1193,move forward,3.375
1194,measurement period,3.37192118226601
1195,increase significantly,3.360655737704918
1196,country basis,3.356378915202445
1197,option,3.355593607305936
1198,multiple deliverable,3.3461538461538463
1199,company,3.339022334597556
1200,cost,3.338095238095238
1201,company,3.3375474083438688
1202,ann ann,3.3333333333333335
1203,acquiring developing,3.333333333333333
1204,manner,3.333333333333333
1205,impairment analysis,3.3239195549850233
1206,negative impact,3.32258064516129
1207,import offer,3.321637426900585
1208,industry standard,3.3191489361702127
1209,fourth quarter,3.3076923076923075
1210,party,3.3
1211,considered probable,3.2976190476190474
1212,estimated fair,3.2947045707915272
1213,effective date,3.2941176470588234
1214,combined entity,3.291871921182266
1215,company,3.2914032869785084
1216,treatment burden,3.2888888888888888
1217,amortized based,3.287562189054726
1218,measurement,3.2857142857142856
1219,core principle,3.2857142857142856
1220,regeneron editas,3.280196953377443
1221,business circumstance,3.2779411764705886
1222,part,3.2777777777777777
1223,information,3.2731147540983607
1224,impairment evaluation,3.268170426065163
1225,develop make,3.2672413793103448
1226,million million,3.2595744680851064
1227,company,3.255689001264223
1228,development manufacture,3.253968253968254
1229,judgment,3.25
1230,liability,3.2495238095238097
1231,agreement subject,3.248665425201738
1232,company,3.2464297420049633
1233,royalty term,3.243691241959426
1234,issuance cost,3.2423505572441744
1235,million share,3.2394129024917513
1236,company option,3.236282608570159
1237,share attributable,3.2346256684491976
1238,regeneron exercise,3.214967544864452
1239,required vote,3.2131147540983607
1240,complete development,3.2103174603174605
1241,earlier terminated,3.2083333333333335
1242,pipeline product,3.196309963099631
1243,result,3.1794642857142854
1244,march results,3.1772727272727272
1245,regeneron challenge,3.1742268041237116
1246,issuance date,3.154255319148936
1247,based expire,3.154228855721393
1248,operation research,3.153900409084497
1249,research,3.1518364255963647
1250,asset,3.1455755433087242
1251,life,3.12089552238806
1252,standalone fair,3.11043956043956
1253,company,3.1056890012642224
1254,asset,3.1036486922828543
1255,administered directly,3.1
1256,excluded form,3.091097308488613
1257,fully paid,3.0811688311688314
1258,operation,3.0810113519091846
1259,total fair,3.0711538461538463
1260,company,3.0709063925685705
1261,preliminary fair,3.0628205128205126
1262,contract,3.0584415584415585
1263,million depreciation,3.0508398656215006
1264,estimate,3.0426829268292686
1265,company,3.0414032869785084
1266,included million,3.0396232996163235
1267,share,3.0194617340229684
1268,california regents,3.018604651162791
1269,step process,3.017857142857143
1270,company,3.005689001264223
1271,company,3.005689001264223
1272,million increase,2.990442971747471
1273,plan,2.9871575342465753
1274,company,2.967227462802684
1275,level input,2.96468253968254
1276,subject treated,2.9434343434343435
1277,regents royalty,2.9069767441860463
1278,company,2.9056890012642222
1279,expect general,2.8842105263157896
1280,amount,2.8814935064935066
1281,company,2.880689001264223
1282,company,2.839022334597556
1283,circumstance,2.823529411764706
1284,regents,2.818604651162791
1285,company,2.8107737470269347
1286,life,2.8
1287,company,2.798371928093491
1288,event change,2.7857142857142856
1289,operations,2.7846153846153845
1290,month,2.782608695652174
1291,validity scope,2.7777777777777777
1292,funding,2.764705882352941
1293,discount rate,2.758928571428571
1294,developing ava,2.75
1295,maintenance,2.75
1296,january follow,2.741071428571429
1297,sublicensees,2.738888888888889
1298,party file,2.7222222222222223
1299,recognized fair,2.701238591916558
1300,company,2.693189001264223
1301,maximum,2.6923076923076925
1302,company,2.6875071830824044
1303,fee,2.6792452830188678
1304,condensed,2.6774193548387095
1305,calculated fair,2.659311740890688
1306,october,2.6565656565656566
1307,initiate,2.6363636363636362
1308,held invalid,2.6285714285714286
1309,ava,2.625
1310,holder,2.5714285714285716
1311,thousand depreciation,2.5410526315789475
1312,retrospective,2.5384615384615383
1313,additional,2.4909090909090907
1314,clinical,2.4725274725274726
1315,generate,2.4705882352941178
1316,allocation,2.4545454545454546
1317,filing,2.4285714285714284
1318,settlement doe,2.4166666666666665
1319,payment,2.4150943396226414
1320,application,2.4
1321,written,2.4
1322,limited,2.4
1323,net,2.3859649122807016
1324,due,2.380952380952381
1325,operation,2.3640522875816994
1326,outstanding,2.3333333333333335
1327,warrant,2.3333333333333335
1328,higher,2.3333333333333335
1329,premium,2.3333333333333335
1330,november,2.3333333333333335
1331,trial,2.328125
1332,purchase,2.326530612244898
1333,preclinical,2.3181818181818183
1334,expense,2.3165829145728645
1335,pursuant,2.3076923076923075
1336,meeting,2.3
1337,fiscal,2.2916666666666665
1338,cornell,2.2857142857142856
1339,ind,2.2777777777777777
1340,concern,2.272727272727273
1341,therapy,2.263157894736842
1342,defending,2.25
1343,sec,2.25
1344,regenxbio,2.25
1345,common,2.2403846153846154
1346,significant,2.24
1347,inserm,2.238095238095238
1348,cash,2.2327586206896552
1349,issued,2.232142857142857
1350,officer,2.230769230769231
1351,study,2.2291666666666665
1352,amended,2.2195121951219514
1353,obligation,2.2195121951219514
1354,equal,2.210526315789474
1355,annual,2.2083333333333335
1356,recognition,2.2
1357,paying,2.2
1358,totaling,2.2
1359,contributed,2.2
1360,fund,2.1944444444444446
1361,market,2.191780821917808
1362,data,2.1875
1363,requires,2.1875
1364,disease,2.1842105263157894
1365,announced,2.1818181818181817
1366,beginning,2.1739130434782608
1367,exclusive,2.169230769230769
1368,license,2.158371040723982
1369,nature,2.1578947368421053
1370,facility,2.1538461538461537
1371,entirety,2.1538461538461537
1372,current,2.1515151515151514
1373,service,2.1496062992125986
1374,program,2.1481481481481484
1375,university,2.142857142857143
1376,focused,2.142857142857143
1377,accounting,2.138888888888889
1378,approximately,2.1379310344827585
1379,securities,2.1363636363636362
1380,deferred,2.1363636363636362
1381,statement,2.13265306122449
1382,closing,2.1296296296296298
1383,rare,2.125
1384,proceeds,2.125
1385,property,2.121212121212121
1386,milestone,2.1204819277108435
1387,offering,2.12
1388,consideration,2.111111111111111
1389,expression,2.111111111111111
1390,exchange,2.109090909090909
1391,planned,2.1052631578947367
1392,potential,2.1016949152542375
1393,government,2.1
1394,period,2.086206896551724
1395,permitted,2.0833333333333335
1396,comparable,2.0833333333333335
1397,amp,2.0833333333333335
1398,amortization,2.0833333333333335
1399,goodwill,2.078125
1400,prior,2.075
1401,september,2.074074074074074
1402,equipment,2.073170731707317
1403,adverum,2.0714285714285716
1404,presented,2.066666666666667
1405,information,2.06
1406,mid,2.0588235294117645
1407,compensation,2.0555555555555554
1408,activity,2.0543478260869565
1409,excluded,2.0434782608695654
1410,aggregate,2.033333333333333
1411,development,2.0317460317460316
1412,entered,2.018181818181818
1413,adoption,2.0163934426229506
1414,stockholder,2.0
1415,award,2.0
1416,hold,2.0
1417,observable,2.0
1418,substantially,2.0
1419,accrued,2.0
1420,normal,2.0
1421,indemnification,2.0
1422,outcome,2.0
1423,approved,2.0
1424,professor,2.0
1425,ataxia,2.0
1426,exchanged,2.0
1427,patient,2.0
1428,exclusivity,2.0
1429,agency,2.0
1430,allocating,2.0
1431,stage,2.0
1432,defendant,2.0
1433,federal,2.0
1434,product,1.996309963099631
1435,future,1.991304347826087
1436,annapurna,1.9863013698630136
1437,impairment,1.9824561403508771
1438,vector,1.9791666666666667
1439,basis,1.974025974025974
1440,collaboration,1.972972972972973
1441,advm,1.9722222222222223
1442,research,1.9676258992805755
1443,considered,1.9642857142857142
1444,patent,1.9607843137254901
1445,acquired,1.9523809523809523
1446,executive,1.95
1447,june,1.9466666666666668
1448,revenue,1.9432624113475176
1449,granted,1.9393939393939394
1450,lease,1.9285714285714286
1451,model,1.9285714285714286
1452,march,1.9272727272727272
1453,commercialization,1.9253731343283582
1454,business,1.925
1455,consulting,1.9230769230769231
1456,elect,1.9166666666666667
1457,interim,1.911764705882353
1458,loss,1.9090909090909092
1459,provide,1.9047619047619047
1460,transaction,1.9
1461,estimated,1.8985507246376812
1462,incurred,1.894736842105263
1463,reserved,1.8888888888888888
1464,payroll,1.8888888888888888
1465,abandonment,1.8888888888888888
1466,bankruptcy,1.8888888888888888
1467,asu,1.8837209302325582
1468,process,1.875
1469,source,1.875
1470,full,1.8695652173913044
1471,decrease,1.8695652173913044
1472,year,1.8686131386861313
1473,approximates,1.8571428571428572
1474,sufficient,1.85
1475,sale,1.8487394957983194
1476,technology,1.8484848484848484
1477,disclosure,1.8461538461538463
1478,assumption,1.8421052631578947
1479,asset,1.8404907975460123
1480,cost,1.838095238095238
1481,presentation,1.8333333333333333
1482,infrastructure,1.8333333333333333
1483,recorded,1.831858407079646
1484,combined,1.8275862068965518
1485,management,1.8245614035087718
1486,based,1.8208955223880596
1487,equity,1.8181818181818181
1488,underwriter,1.8181818181818181
1489,liability,1.8095238095238095
1490,requirement,1.8076923076923077
1491,editas,1.8059701492537314
1492,acquisition,1.8028169014084507
1493,employee,1.8
1494,designed,1.8
1495,liquidity,1.8
1496,customers,1.8
1497,additionally,1.8
1498,report,1.794871794871795
1499,effort,1.794871794871795
1500,recognize,1.7857142857142858
1501,completed,1.7857142857142858
1502,contract,1.7727272727272727
1503,advancing,1.7692307692307692
1504,april,1.7647058823529411
1505,deficiency,1.7619047619047619
1506,agreement,1.7597765363128492
1507,term,1.7553191489361701
1508,date,1.75
1509,applicable,1.75
1510,purchased,1.75
1511,allocated,1.75
1512,table,1.75
1513,make,1.75
1514,note,1.7413793103448276
1515,exercise,1.7407407407407407
1516,amount,1.7386363636363635
1517,level,1.7361111111111112
1518,litigation,1.7333333333333334
1519,option,1.730593607305936
1520,condition,1.7291666666666667
1521,target,1.7272727272727273
1522,meet,1.7272727272727273
1523,advance,1.7254901960784315
1524,performing,1.7142857142857142
1525,applied,1.7142857142857142
1526,pending,1.7142857142857142
1527,standalone,1.7142857142857142
1528,reflect,1.7142857142857142
1529,observe,1.7142857142857142
1530,indication,1.711111111111111
1531,unit,1.7037037037037037
1532,adjustment,1.7037037037037037
1533,defined,1.7
1534,vesting,1.7
1535,general,1.7
1536,challenge,1.7
1537,sell,1.6956521739130435
1538,modified,1.6875
1539,total,1.675
1540,portfolio,1.6666666666666667
1541,exception,1.6666666666666667
1542,summary,1.6666666666666667
1543,active,1.6666666666666667
1544,fixed,1.6666666666666667
1545,retina,1.6666666666666667
1546,differ,1.6666666666666667
1547,method,1.6666666666666667
1548,expertise,1.6666666666666667
1549,nasdaq,1.6666666666666667
1550,attributed,1.6666666666666667
1551,preliminary,1.6666666666666667
1552,earlier,1.6666666666666667
1553,ann,1.6666666666666667
1554,review,1.6666666666666667
1555,expires,1.6666666666666667
1556,medicine,1.6486486486486487
1557,distribution,1.6428571428571428
1558,breach,1.64
1559,receive,1.6363636363636365
1560,timing,1.6341463414634145
1561,million,1.6297872340425532
1562,delivery,1.625
1563,reduce,1.625
1564,exercised,1.625
1565,attributable,1.625
1566,event,1.619047619047619
1567,share,1.6096256684491979
1568,support,1.606060606060606
1569,director,1.606060606060606
1570,february,1.6
1571,california,1.6
1572,directly,1.6
1573,adopted,1.6
1574,adopt,1.6
1575,leases,1.6
1576,address,1.6
1577,collaborations,1.6
1578,performed,1.59375
1579,grant,1.5909090909090908
1580,result,1.5857142857142856
1581,risk,1.5789473684210527
1582,effect,1.575
1583,discount,1.5714285714285714
1584,agreed,1.5714285714285714
1585,contracted,1.5714285714285714
1586,central,1.5714285714285714
1587,anticipate,1.5714285714285714
1588,commitments,1.5714285714285714
1589,determined,1.565217391304348
1590,cover,1.5625
1591,action,1.5588235294117647
1592,include,1.5555555555555556
1593,fda,1.5555555555555556
1594,indicative,1.5555555555555556
1595,fully,1.5454545454545454
1596,october,1.5454545454545454
1597,december,1.5444444444444445
1598,effective,1.5441176470588236
1599,terminated,1.5416666666666667
1600,claim,1.5416666666666667
1601,paid,1.5357142857142858
1602,day,1.5333333333333334
1603,develop,1.5172413793103448
1604,company,1.5056890012642226
1605,party,1.5
1606,expected,1.5
1607,derived,1.5
1608,uncertainty,1.5
1609,judgment,1.5
1610,involved,1.5
1611,successful,1.5
1612,administered,1.5
1613,debilitating,1.5
1614,evaluates,1.5
1615,indicator,1.5
1616,default,1.5
1617,payments,1.5
1618,adeno,1.5
1619,transparency,1.5
1620,fails,1.5
1621,denied,1.5
1622,treat,1.5
1623,subject,1.488888888888889
1624,royalty,1.4883720930232558
1625,termination,1.4848484848484849
1626,regeneron,1.4742268041237114
1627,exist,1.4705882352941178
1628,amortized,1.4666666666666666
1629,entity,1.4642857142857142
1630,goal,1.4615384615384615
1631,payable,1.4615384615384615
1632,discussed,1.4615384615384615
1633,noted,1.4615384615384615
1634,treated,1.4545454545454546
1635,valued,1.4545454545454546
1636,adjusted,1.4444444444444444
1637,scope,1.4444444444444444
1638,reason,1.4444444444444444
1639,measured,1.44
1640,held,1.4285714285714286
1641,follow,1.4285714285714286
1642,low,1.4285714285714286
1643,plan,1.4246575342465753
1644,depreciation,1.4210526315789473
1645,rsus,1.4193548387096775
1646,regents,1.4186046511627908
1647,accounted,1.4166666666666667
1648,ava,1.4166666666666667
1649,maturity,1.411764705882353
1650,included,1.4098360655737705
1651,issuance,1.4042553191489362
1652,operations,1.4
1653,decided,1.4
1654,assistance,1.4
1655,australian,1.4
1656,continues,1.4
1657,wamd,1.4
1658,fair,1.396153846153846
1659,arrangement,1.393939393939394
1660,comparison,1.3846153846153846
1661,country,1.3823529411764706
1662,forward,1.375
1663,ass,1.375
1664,detail,1.375
1665,tap,1.375
1666,number,1.3703703703703705
1667,increase,1.360655737704918
1668,circumstance,1.3529411764705883
1669,deliverable,1.3461538461538463
1670,investment,1.3421052631578947
1671,analysis,1.3414634146341464
1672,developing,1.3333333333333333
1673,probable,1.3333333333333333
1674,caused,1.3333333333333333
1675,dose,1.3333333333333333
1676,affect,1.3333333333333333
1677,changed,1.3333333333333333
1678,represents,1.3333333333333333
1679,manner,1.3333333333333333
1680,expire,1.3333333333333333
1681,drawn,1.3333333333333333
1682,vested,1.3333333333333333
1683,clarifies,1.3333333333333333
1684,extension,1.3333333333333333
1685,validity,1.3333333333333333
1686,conduct,1.3333333333333333
1687,impact,1.3225806451612903
1688,standard,1.3191489361702127
1689,january,1.3125
1690,performance,1.3125
1691,quarter,1.3076923076923077
1692,expiration,1.3076923076923077
1693,recognized,1.305084745762712
1694,life,1.3
1695,estimate,1.2926829268292683
1696,time,1.2894736842105263
1697,treatment,1.288888888888889
1698,principle,1.2857142857142858
1699,evaluation,1.2857142857142858
1700,measurement,1.2857142857142858
1701,holder,1.2857142857142858
1702,estimating,1.2857142857142858
1703,exercising,1.2857142857142858
1704,adjust,1.2857142857142858
1705,part,1.2777777777777777
1706,settlement,1.2666666666666666
1707,calculated,1.263157894736842
1708,phase,1.2580645161290323
1709,met,1.25
1710,results,1.25
1711,eye,1.25
1712,care,1.25
1713,sublicensees,1.25
1714,july,1.2285714285714286
1715,input,1.2285714285714286
1716,manufacture,1.2222222222222223
1717,file,1.2222222222222223
1718,required,1.2131147540983607
1719,offer,1.2105263157894737
1720,commercialize,1.2083333333333333
1721,pipeline,1.2
1722,triggered,1.2
1723,route,1.2
1724,invalid,1.2
1725,august,1.1875
1726,account,1.1875
1727,rate,1.1875
1728,operation,1.1862745098039216
1729,expect,1.1842105263157894
1730,concluded,1.1818181818181819
1731,complete,1.1785714285714286
1732,continue,1.1777777777777778
1733,respect,1.1724137931034482
1734,change,1.1666666666666667
1735,added,1.1666666666666667
1736,accrual,1.1666666666666667
1737,probability,1.1666666666666667
1738,doe,1.15
1739,carrying,1.1428571428571428
1740,step,1.1428571428571428
1741,anniversary,1.1428571428571428
1742,board,1.1333333333333333
1743,generated,1.125
1744,collaborate,1.125
1745,thousand,1.12
1746,friedreich,1.1111111111111112
1747,evaluating,1.105263157894737
1748,set,1.1
1749,msa,1.0952380952380953
1750,needed,1.0909090909090908
1751,classified,1.0769230769230769
1752,pay,1.0625
1753,espp,1.0625
1754,terminate,1.0579710144927537
1755,form,1.0476190476190477
1756,obtain,1.0416666666666667
1757,delaware,1.0
1758,headquartered,1.0
1759,discovering,1.0
1760,chronic,1.0
1761,inception,1.0
1762,expands,1.0
1763,engages,1.0
1764,shareholder,1.0
1765,contributors,1.0
1766,representative,1.0
1767,acquire,1.0
1768,converted,1.0
1769,relate,1.0
1770,nearest,1.0
1771,case,1.0
1772,contributor,1.0
1773,connection,1.0
1774,close,1.0
1775,occurred,1.0
1776,execution,1.0
1777,approve,1.0
1778,failure,1.0
1779,communicated,1.0
1780,writing,1.0
1781,offerings,1.0
1782,resulted,1.0
1783,prepared,1.0
1784,accordance,1.0
1785,gaap,1.0
1786,rule,1.0
1787,footnote,1.0
1788,omitted,1.0
1789,read,1.0
1790,conjunction,1.0
1791,preparation,1.0
1792,consistent,1.0
1793,contracts,1.0
1794,supersedes,1.0
1795,depict,1.0
1796,transfer,1.0
1797,good,1.0
1798,customer,1.0
1799,reflects,1.0
1800,entitled,1.0
1801,fulfill,1.0
1802,uncertainties,1.0
1803,ability,1.0
1804,evaluate,1.0
1805,perform,1.0
1806,type,1.0
1807,alleviate,1.0
1808,amends,1.0
1809,classification,1.0
1810,aimed,1.0
1811,transparent,1.0
1812,lessee,1.0
1813,aspect,1.0
1814,sold,1.0
1815,measurements,1.0
1816,hierarchy,1.0
1817,corroborated,1.0
1818,supported,1.0
1819,assessment,1.0
1820,significance,1.0
1821,pricing,1.0
1822,certificate,1.0
1823,deposit,1.0
1824,reimburse,1.0
1825,obligated,1.0
1826,achievement,1.0
1827,achieved,1.0
1828,determinable,1.0
1829,commitment,1.0
1830,indemnifications,1.0
1831,variety,1.0
1832,representation,1.0
1833,warranty,1.0
1834,exposure,1.0
1835,unknown,1.0
1836,made,1.0
1837,defend,1.0
1838,limit,1.0
1839,serving,1.0
1840,request,1.0
1841,capacity,1.0
1842,minimal,1.0
1843,range,1.0
1844,filed,1.0
1845,behalf,1.0
1846,person,1.0
1847,allege,1.0
1848,thing,1.0
1849,prospect,1.0
1850,state,1.0
1851,county,1.0
1852,merit,1.0
1853,intend,1.0
1854,assurance,1.0
1855,defense,1.0
1856,predict,1.0
1857,matter,1.0
1858,consultant,1.0
1859,authorized,1.0
1860,establishment,1.0
1861,difference,1.0
1862,nonemployees,1.0
1863,entitle,1.0
1864,employees,1.0
1865,earned,1.0
1866,section,1.0
1867,code,1.0
1868,participant,1.0
1869,defer,1.0
1870,portion,1.0
1871,dividing,1.0
1872,computed,1.0
1873,antidilutive,1.0
1874,computation,1.0
1875,discussion,1.0
1876,addition,1.0
1877,meaning,1.0
1878,leveraged,1.0
1879,focusing,1.0
1880,australia,1.0
1881,conducted,1.0
1882,majority,1.0
1883,half,1.0
1884,inform,1.0
1885,negotiation,1.0
1886,initiated,1.0
1887,working,1.0
1888,evaluated,1.0
1889,juvenile,1.0
1890,carry,1.0
1891,prepare,1.0
1892,unable,1.0
1893,forced,1.0
1894,eliminate,1.0
1895,receivable,1.0
1896,cros,1.0
1897,expensed,1.0
1898,delivered,1.0
1899,expended,1.0
1900,communication,1.0
1901,success,1.0
1902,expectation,1.0
1903,refund,1.0
1904,depend,1.0
1905,reduction,1.0
1906,reimbursement,1.0
1907,extent,1.0
1908,estimates,1.0
1909,base,1.0
1910,reasonable,1.0
1911,invest,1.0
1912,comprised,1.0
1913,order,1.0
1914,build,1.0
1915,pursue,1.0
1916,seeking,1.0
1917,food,1.0
1918,require,1.0
1919,progress,1.0
1920,expand,1.0
1921,preparing,1.0
1922,degree,1.0
1923,enforcing,1.0
1924,enter,1.0
1925,emergence,1.0
1926,prefer,1.0
1927,completion,1.0
1928,wednesday,1.0
1929,thursday,1.0
1930,opinion,1.0
1931,longer,1.0
1932,fact,1.0
1933,recovery,1.0
1934,comparing,1.0
1935,forecast,1.0
1936,occur,1.0
1937,tested,1.0
1938,aware,1.0
1939,obtained,1.0
1940,point,1.0
1941,abandoned,1.0
1942,excess,1.0
1943,apply,1.0
1944,resource,1.0
1945,receiving,1.0
1946,founder,1.0
1947,existence,1.0
1948,qualify,1.0
1949,valuing,1.0
1950,component,1.0
1951,summarized,1.0
1952,nominal,1.0
1953,assigned,1.0
1954,deductible,1.0
1955,frequently,1.0
1956,determine,1.0
1957,couple,1.0
1958,corroboration,1.0
1959,extended,1.0
1960,responsible,1.0
1961,eligible,1.0
1962,profit,1.0
1963,end,1.0
1964,convenience,1.0
1965,totality,1.0
1966,cured,1.0
1967,initiation,1.0
1968,dissolution,1.0
1969,enforceability,1.0
1970,department,1.0
1971,allergen,1.0
1972,utilize,1.0
1973,achieve,1.0
1974,aavrh,1.0
1975,facilitate,1.0
1976,intended,1.0
1977,finance,1.0
1978,recruitment,1.0
1979,scheduled,1.0
1980,accrues,1.0
1981,invoiced,1.0
1982,motion,1.0
1983,dismiss,1.0
1984,essentially,1.0
1985,stay,1.0
1986,credited,1.0
1987,france,1.0
1988,clarification,1.0
1989,repay,1.0
1990,investigational,1.0
1991,withdraw,1.0
1992,president,1.0
1993,minimize,1.0
1994,surgical,1.0
1995,provision,1.0
1996,providing,1.0
1997,improvement,1.0
1998,preliminarily,1.0
1999,comparability,1.0
2000,amendment,1.0
2001,temporary,1.0
2002,covering,1.0
2003,treating,1.0
2004,field,1.0
2005,extend,1.0
2006,reaching,1.0
2007,developed,1.0
2008,prosecution,1.0
2009,insolvent,1.0
2010,unenforceable,1.0
2011,extending,1.0
2012,place,1.0
2013,dispute,1.0
2014,decision,1.0
2015,complies,1.0
2016,originally,1.0
2017,invalidation,1.0
2018,affiliate,1.0
2019,commence,1.0
2020,regenexbio,1.0
2021,licensors,1.0
2022,declare,1.0
2023,render,1.0
2024,voluntary,1.0
2025,escalation,1.0
2026,settle,1.0
2027,remainder,1.0
2028,insurer,1.0
2029,deny,1.0
2030,assign,1.0
2031,admission,1.0
2032,estimable,1.0
2033,leveraging,1.0
2034,led,1.0
2035,team,1.0
2036,aflibercept,1.0
2037,testing,1.0
2038,commercializing,1.0
2039,vendor,1.0
2040,compared,1.0
